# Early Conversion of Dasatinib in CML-CP Patients

> **NCT04136015** · — · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Validity and Safety

## Interventions

- **DRUG:** Dasatinib 100 MG

## Key facts

- **NCT ID:** NCT04136015
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-22
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04136015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04136015, "Early Conversion of Dasatinib in CML-CP Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04136015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*